Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Characterization of INCB00928, a Potent and Selective ALK2 Inhibitor for the Treatment of Anemia

Yaoyu Chen, Matthew C. Stubbs, PhD, Michelle Pusey, Xiaoming Wen, Robert J. Collins, Kanishk Kapilashrami, Mark Rupar, Pramod Thekkat, Luping Lin, PhD, Kevin Bowman, Yan-ou Yang, Sharon Diamond, Swamy Yeleswaram, PhD, Sunkyu Kim, Holly K. Koblish, PhD, Yingnan Chen, Susan Wee, PhD BS

Blood (2020) 136 (Supplement 1): 52.

https://doi.org/10.1182/blood-2020-136138

Published: 2020

Journal Articles

Population Pharmacokinetics of Ruxolitinib in Patients with aGVHD Who Had an Inadequate Response to Corticosteroids

Xuejun Chen, Xiang Liu, Phillip Wang, Swamy Yeleswaram, PhD

Blood (2019) 134 (Supplement_1): 4534.

https://doi.org/10.1182/blood-2019-124027

Published: 2019

Journal Articles

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Andres Forero-Torres, MD, Rod Ramchandren, MD, Abdulraheem Yacoub, MD, Michael S. Wertheim, MD, William J. Edenfield, MD, Paolo Caimi, MD, Martin Gutierrez, MD, Luke Akard, MD, Carolina Escobar, MD, Justin Call, MD, Daniel Persky, MD, Swami P. Iyer, MD, Douglas J. DeMarini, PhD, Li Zhou, PhD, Swamy Yeleswaram, PhD, Tycel J. Phillips, MD

Blood (2017) 130 (Supplement 1): 410.

https://doi.org/10.1182/blood.V130.Suppl_1.410.410

Published: 2017

Journal Articles

Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies

Andres Forero-Torres, MD, Seth Rosen, MD, David C. Smith, MD, Glenn Lesser, MD, Julio Peguero, MD, Shilpa Gupta, MD, Justin M. Watts, MD, Marcus Noel, MD, Razelle Kurzrock, MD, Haeseong Park, MD, Patricia LoRusso, DO, Catherine C. Coombs, MD, Fred Zheng, MD, Julie Switzky, RN, Swamy Yeleswaram, PhD, Gerald Falchook, MD

Blood (2017) 130 (Supplement 1): 4048.

https://doi.org/10.1182/blood.V130.Suppl_1.4048.4048

Published: 2017

Journal Articles

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Tycel Phillips, MD, Rod Ramchandren, MD, Michael S Wertheim, MD, Martin E Gutierrez, MD, William J Edenfield, MD, Fitzroy Dawkins, MD, Doug J DeMarini, Li Zhou, PhD, Swamy Yeleswaram, PhD, Robert C Newton, PhD, Xuejun Chen, PhD, Andres Forero-Torres, MD

Blood (2016) 128 (22): 4195.

https://doi.org/10.1182/blood.V128.22.4195.4195

Published: 2016

Journal Articles

LSD1 Inhibition Induces Fetal Hemoglobin Expression and Provides a Novel Therapeutic Approach to Sickle Cell Disease

Blood (2016) 128 (22): 2472.

https://doi.org/10.1182/blood.V128.22.2472.2472

Published: 2016

Journal Articles

INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF).

Ruben A. Mesa, MD, FACP, Srdan Verstovsek, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Steven Friedman, MD, Robert Newton, Susan Erickson-Viitanen, Deborah Hunter, John Redman, MD, Swamy Yeleswaram, Edward Bradley, MD, Ayalew Tefferi, MD

Blood (2008) 112 (11): 1760.

https://doi.org/10.1182/blood.V112.11.1760.1760

Published: 2008

NARROW

Characterization of INCB00928, a Potent and Selective ALK2 Inhibitor for the Treatment of Anemia

Population Pharmacokinetics of Ruxolitinib in Patients with aGVHD Who Had an Inadequate Response to Corticosteroids

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

LSD1 Inhibition Induces Fetal Hemoglobin Expression and Provides a Novel Therapeutic Approach to Sickle Cell Disease

INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF).

Email alerts

ASH Publications

American Society of Hematology

Characterization of INCB00928, a Potent and Selective ALK2 Inhibitor for the Treatment of Anemia

Population Pharmacokinetics of Ruxolitinib in Patients with aGVHD Who Had an Inadequate Response to Corticosteroids

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Preliminary Results from an Ongoing Phase 1/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in Patients (pts) with Advanced Malignancies

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

LSD1 Inhibition Induces Fetal Hemoglobin Expression and Provides a Novel Therapeutic Approach to Sickle Cell Disease

INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only